key: cord-0743692-75y3rs6p authors: Xu, Chang; Yu, Tianqi; Furuya-Kanamori, Luis; Lin, Lifeng; Zorzela, Liliane; Zhou, Xiaoqin; Dai, Hanming; Loke, Yoon; Vohra, Sunita title: Validity of data extraction in evidence synthesis practice of adverse events: reproducibility study date: 2022-05-10 journal: BMJ DOI: 10.1136/bmj-2021-069155 sha: 01065a1dc810eb398ada7350705fc18993308e28 doc_id: 743692 cord_uid: 75y3rs6p OBJECTIVES: To investigate the validity of data extraction in systematic reviews of adverse events, the effect of data extraction errors on the results, and to develop a classification framework for data extraction errors to support further methodological research. DESIGN: Reproducibility study. DATA SOURCES: PubMed was searched for eligible systematic reviews published between 1 January 2015 and 1 January 2020. Metadata from the randomised controlled trials were extracted from the systematic reviews by four authors. The original data sources (eg, full text and ClinicalTrials.gov) were then referred to by the same authors to reproduce the data used in these meta-analyses. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Systematic reviews were included when based on randomised controlled trials for healthcare interventions that reported safety as the exclusive outcome, with at least one pair meta-analysis that included five or more randomised controlled trials and with a 2×2 table of data for event counts and sample sizes in intervention and control arms available for each trial in the meta-analysis. MAIN OUTCOME MEASURES: The primary outcome was data extraction errors summarised at three levels: study level, meta-analysis level, and systematic review level. The potential effect of such errors on the results was further investigated. RESULTS: 201 systematic reviews and 829 pairwise meta-analyses involving 10 386 randomised controlled trials were included. Data extraction could not be reproduced in 1762 (17.0%) of 10 386 trials. In 554 (66.8%) of 829 meta-analyses, at least one randomised controlled trial had data extraction errors; 171 (85.1%) of 201 systematic reviews had at least one meta-analysis with data extraction errors. The most common types of data extraction errors were numerical errors (49.2%, 867/1762) and ambiguous errors (29.9%, 526/1762), mainly caused by ambiguous definitions of the outcomes. These categories were followed by three others: zero assumption errors, misidentification, and mismatching errors. The impact of these errors were analysed on 288 meta-analyses. Data extraction errors led to 10 (3.5%) of 288 meta-analyses changing the direction of the effect and 19 (6.6%) of 288 meta-analyses changing the significance of the P value. Meta-analyses that had two or more different types of errors were more susceptible to these changes than those with only one type of error (for moderate changes, 11 (28.2%) of 39 v 26 (10.4%) 249, P=0.002; for large changes, 5 (12.8%) of 39 v 8 (3.2%) of 249, P=0.01). CONCLUSION: Systematic reviews of adverse events potentially have serious issues in terms of the reproducibility of the data extraction, and these errors can mislead the conclusions. Implementation guidelines are urgently required to help authors of future systematic reviews improve the validity of data extraction. Reason: Some meta-analyses claimed they included phrase II or II trials, and did not mention whether these were RCTs or not. Based on our experience, the majority were RCTs. Therefore, we expand the inclusion criteria from RCTs to clinical trials. During the data extraction, we noticed many of the systematic reviews failed to report or conduct the risk of bias of each trial. After an online meeting, we decided to assess the risk of bias by our research team. Two assistants added in the research, with background of evidence-based medicine. They take charges of the assessment of risk of bias. Since the assessment of ROB is of some subjective, the two assistants are blinded, they were not and will not informed the aim of the project and the potential comparisons. And the assessment of risk of bias will be started after the finish of the data extraction (possibly at July). Change in analysis of the main outcomes: We primarily plan to limit RCTs with 1: 1 design to facilitate the estimation of the ORs in the case of zeroevents. But then after our recent simulation study, we found continuity 11 correction works well even when the ratio ranges from 0.51 to 1.99, therefore we "relaxed" the limits to 0.51 to 1.99. We primarily collected data of the clinical trials from the systematic reviews, while for the sample we finished (accounted for 1/3 of the total), we found that many of the data were incorrectly recorded by these systematic reviews. Based on an urgent online meeting (CX and TQ), we decided to re-do the data extraction, directly from the original studies. Online meeting with a pharmacist about the definition of different treatments/controls. Some clinical trials may have a flexible treatment schedule, for example, they use A drug with 5 mg at week 1, and 10 mg at week 2, and 20 mg at week 3, and then continue 20 mg for the following 11 weeks. Makes it difficult to extract the dose. After a discussion (CX and TQ), we decided to use the maximum dose in our study. 14-June, 2021 Add the tools that will be used for ROB assessment. Add information for extraction: whether the trials involve two periods, and the design (double/single blind, open label) of each period. Two assistants (WJ, FY) are ready to start the assessment of the ROB. An online meeting is held discussing the use of ROB 2 (XC, TQ, WJ, FY). A prior training for the two assistants based on 5 trials is prepared and will start tomorrow. The second online meeting will be held after the training for a further discussion of any issues during the preliminary assessment. We finished about 50% of the systematic reviews for the intended data collection, and the included trials of these systematic reviews are ready for the ROB assessment. For the rest 50%, we may finish it 3 weeks later, and as long as we finish, we will prepare the trials included in these reviews for WJ and FY for the ROB assessment. The two assistants finished the first period training of 2 RCTs; there are many disagreements between them on the judgement of each item. Thus, an online 12 meeting is held discussion the issues of the assessment of each domain, each item, by reading the explanation of the ROB 2. After 1 hour's discussion, an agreement is achieved of the assessment criteria. And the two assistants will continue to assess the remaining 3 RCTs for training. The two assistants finished the remaining 3 RCTs, and an online meeting is held to discuss further issues they met during the assessment. There is a high agreement of the judgement of the items this time and only 3 minor points involved. The training is now finished, and they are ready to formally start the assessment of the ROB. During the data extraction of the meta-analysis data from original RCTs, we recorded many pieces of incorrect information of these meta-analyses. We then decided to treat this as an additional project that investigated how many meta-analyses with the data were incorrect. In this additional project, we will add systematic reviews other than drug/biologics treatment in order to increase the representativeness of the dataset. Both the data obtained from the meta-analyses and the data obtained from original RCTs will be recorded. We will first investigate the proportions that systematic reviews failed to extract the correct 2 x 2 table data; we will also record the type of incorrection; we will further compare the meta-analysis based on correct data to the incorrect one to see how the incorrection impact the results. Another assistant (Z.XQ) will take charge of the data extraction for systematic reviews other than drug/biologics treatments. The data will then be double-checked by the assistant after she finishes it. 15-July, 2021 XC and DMH finished the data extraction of SRs assigned to them, and started double-checking the data they extracted. Until now, XC checked for 571 rows of 2 by 2 table data he extracted from RCTs (with 28 meta-analyses), and found 21 rows were incorrect by himself. The main reason is that RCTs present the same outcome for several times, Table 2 . Urinary tract infection). The estimated proportion of mis-extraction by himself is then 21/571=3.7%. Suggests a high accuracy of the data extraction. However, the mis-extraction also suggests the importance of double-checking process. Therefore, an online meeting (XC, YTQ, and DMH) is then held by XC, and everybody is required to check each cell of the 2 by 2 table very carefully to ensure 0% error. In addition, YTQ and DMH are required to report their own accuracy to XC during their double-checking process. Until now, XC checked for 696 rows of 2 by 2 table data he extracted from RCTs (with 43 meta-analyses), and found 24 rows were incorrect by himself. The estimated proportion of mis-extraction by himself is then 24/696=3.4%. The accuracy is better for the data extracted more recently (3.7% vs. 2.4% [3/125] ). Until now, XC checked for 850 rows of 2 by 2 table data he extracted from RCTs (with 54 meta-analyses), and found 24 rows (no errors from 697-850) were incorrect by himself. The accuracy is 24/850=2.8%. Again, the accuracy is much better for the data extracted more recently (3.7% vs. 2.4% vs. 0%). 20-July, 2021 Z.XQ finished the meta-analytic data (2 by 2 table for each included study) extraction from the forest plot/tables of the meta-analyses other than drug/biologics. She will start the 2 by 2 table data extraction from original RCTs thereafter, and she was required to double-check the data she extracted from meta-analysis and report her accuracy to XC. 27-Aug, 2021 TQ finished the data extraction of the 16 SRs assigned to her, and she will start the double-checking process thereafter. Report by XC: For the remaining 11 SRs with 47 meta-analyses, there were 15 4 errors among 609 rows, with a proportion of 4/609=0.66%. Two for typo errors, and two (one study) for mistakes on the definition of outcome. Report by TQ: For the remaining 16 SRs with 59 meta-analyses, there were 6 errors by herself among 1325 rows, with a proportion of self-error of 6/1325=0.45%, mainly due to typo errors as well as failing to find the outcomes in the first time. A fifth-round checking by TQ finished, which mainly focused on the coding of the ID of systematic review, ID of each meta-analysis, information of subgroups, and eligibility of all systematic reviews. TQ found that 9 systematic reviews should not be excluded and need further data extraction. An online meeting by XC and TQ for the 9 additional systematic reviews, and decide to extract the data by one of the assistants that do not know the summarized results. Hanmin started data extraction for the 9 additional systematic reviews. Increased Risk of Adverse Neurocognitive Outcomes With Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis S-1-based regimens and the risk of leucopenic complications; a Meta-analysis with comparison to other fluoropyrimidines and non fluoropyrimidines Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis Risk of cardiovascular adverse events in patients with solid tumors treated with ramucirumab: A meta analysis and summary of other VEGF targeted agents Risk of hematological toxicities in patients with solid tumors treated with ramucirumab: a meta-analysis Risk of mucocutaneous toxicities in patients with solid tumors treated with lapatinib: a systematic review and meta-analysis Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative systematic review and meta-analysis AbdeSarreated with Immune Checkpoint Inhibitors; a Systematic Review and Meta-analysis Transfusion of fresher vs older red blood cells in hospitalized patients: a systematic review and meta-analysis Intravenous immune globulin and thromboembolic adverse events: A systematic review and meta-analysis of RCTs The safety of intravenous iron preparations: systematic review and meta-analysis Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis Risk of Infections and Cancer in Patients With 27 Rheumatologic Diseases Receiving Interleukin Inhibitors: A Systematic Review and Metaanalysis A systematic review: Are herbal and homeopathic remedies used during pregnancy safe? Serious adverse events reported in placebo randomised controlled trials of oral naltrexone: a systematic review and meta-analysis Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney function Influence of radial versus femoral access site on coronary angiography and intervention outcomes: A systematic review and meta-analysis Long-term (2-5 years) adverse clinical outcomes associated with ZES versus SES Inhaled nitric oxide therapy and risk of renal dysfunction: a systematic review and meta-analysis of randomized trials Infectious complications in lupus nephritis treatment: a systematic review and meta-analysis Effects of Volatile Anesthetics on Mortality and Postoperative Pulmonary and Other Complications in Patients Undergoing Surgery: A Systematic Review and Meta-analysis Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis Treatment-Related Death during Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Studies Comparison of Metal and Plastic Stents for Preoperative Biliary Drainage in Resectable and Borderline Resectable Periampullary Cancer: A Meta-Analysis and System Review Meta-analysis comparing the safety of laparoscopic and open surgical approaches for suspected adnexal mass during the second trimester Safety outcomes of disease-modifying therapies for relapsing-remitting multiple sclerosis: A network meta-analysis Ruxolitinib-associated infections: A systematic review and meta-analysis Safety of insulin analogs during pregnancy: a meta-analysis Surgical complications of primary rhegmatogenous retinal detachment: a meta-analysis A systematic review on the safety of Prostar XL versus ProGlide after TAVR and EVAR Safety of 80% vs 30-35% fraction of inspired oxygen in patients undergoing surgery: a systematic review and meta-analysis Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: A systematic review and meta-analysis Intravitreal Bevacizumab and Cardiovascular Risk in Patients with Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Randomized Controlled Trials and Observational Studies Does Circumcision Increase Meatal Stenosis Risk?-A Systematic Review and Meta-analysis Laparoscopic permanent sigmoid stoma creation through the extraperitoneal route versus transperitoneal route. A meta-analysis of stoma-related complications Bleeding Risks With Aspirin Use for Primary Prevention in Adults: A Systematic Review for the U.S. Preventive Services Task Force Postoperative outcomes in distal hypospadias: a meta-analysis of the Mathieu and tubularized incised plate repair methods for development of urethrocutaneous fistula and urethral stricture The Effect of Renin-Angiotensin-Aldosterone System Blockade Medications on Contrast-Induced Nephropathy in Patients Undergoing Coronary Angiography: A Meta-Analysis Safety of Lipoabdominoplasty Versus Abdominoplasty: A Systematic Review and Meta-analysis A systematic review of complications in thoracic spine surgery for ossification of the posterior longitudinal ligament Safety of aripiprazole for tics in children and adolescents: A systematic review and metaanalysis Postoperative Deep Infection After Cemented Versus Cementless Total Hip Arthroplasty: A Meta -Analysis Clarithromycin use and the risk of mortality and cardiovascular events: A systematic review and metaanalysis Safety of the reuse of needles for subcutaneous insulin injection: A systematic review and meta-analysis Effect of preoperative angiotensin-converting enzyme inhibitor on the outcome of coronary artery bypass graft surgery The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17 inhibitors: A meta-analysis of published trials Less than 5 studies Meta-Analysis Comparing the Relative Risk of Adverse Events for Amiodarone Versus Placebo Safety liver profile of teriflunomide versus interferon β in multiple sclerosis: Systematic review and indirect comparison meta-analysis No 2 by 2 table data Second-generation antipsychotic drugs and short-term somatic serious adverse events: a systematic review and meta-analysis Second-generation antipsychotic drugs and short-term mortality: a systematic review and meta-analysis of placebo-controlled randomised controlled trials Randomized sham-controlled trials in endoscopy: a systematic review and meta-analysis of adverse events The overall safety evaluation of programmed cell death/programmed cell death ligand 1 (PD-1/PD-L1) treatment for lung cancer patients: An updated systematic review and meta-analysis Less than 5 studies Meta-analysis of the adverse events associated with extended-release versus standard immediate-release pramipexole in Parkinson disease Complications from Nasolabial Fold Injection of Calcium Hydroxylapatite for Facial Soft-Tissue Augmentation: A Systematic Review and Meta-Analysis